Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month High – What’s Next?

Compass Therapeutics, Inc. (NASDAQ:CMPX) hit a new 52-week high on Monday . The company traded as high as $5.91 and last traded at $5.79, with a volume of 6806 shares. The stock had previously closed at $5.80.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on CMPX shares. D. Boral Capital reissued a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a report on Wednesday, November 5th. Wall Street Zen upgraded shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Compass Point set a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, October 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. Finally, Lifesci Capital began coverage on shares of Compass Therapeutics in a research note on Monday, October 6th. They set an “outperform” rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $12.90.

Compass Therapeutics Stock Down 4.4%

The company’s 50-day moving average is $4.29 and its two-hundred day moving average is $3.36. The company has a market capitalization of $928.43 million, a P/E ratio of -11.60 and a beta of 1.44.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. On average, sell-side analysts predict that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Institutional Trading of Compass Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC lifted its stake in shares of Compass Therapeutics by 97.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after purchasing an additional 6,951,666 shares during the period. Vivo Capital LLC raised its holdings in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after purchasing an additional 3,502,000 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in Compass Therapeutics during the third quarter valued at $9,892,000. Millennium Management LLC boosted its holdings in shares of Compass Therapeutics by 280.4% during the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock valued at $11,332,000 after buying an additional 2,386,367 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after buying an additional 2,212,794 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.